Condition: Anal Cancer · Anal Carcinoma · Anal Squamous Cell Carcinoma · Sponsor: Herlev Hospital
A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).
This description comes directly from the study's public registry record.
Eva Serup-Hansen, MD, PhD · +4538689084 · eva.serup-hansen@regionh.dk
katrine S storm, MD · +4538686269 · katrine.smedegaard.storm@regionh.dk
Always discuss trial participation with your own doctor first.
| Oncology dept, Herlev and Gentofte Hospital | Herlev, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05438836